Wegovy HD 7.2mg: New Prescription Strength Approved May 2026
The FDA approved Wegovy HD — semaglutide at 7.2mg — on May 13, 2026. At 20.7% average weight loss, it's the most potent single-agent GLP-1 ever approved.
Dose: 7.2mg once-weekly injectable (3x standard 2.4mg)
Trial: STEP UP — 20.7% mean weight loss at 72 weeks
1 in 3 achieved ≥25% body weight loss
Review: 54-day accelerated approval under CNPV pilot
Prescribing Context
Wegovy HD was approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, and for cardiovascular risk reduction in adults with established CVD. The dose escalation schedule builds from the existing Wegovy titration, extending to the 7.2mg maintenance dose.
STEP UP Efficacy Summary
| Outcome | Wegovy HD 7.2mg | Standard 2.4mg |
|---|---|---|
| Mean weight loss | 20.7% | ~15% |
| ≥25% weight loss | ~33% | ~12% |
| Cardiovascular indication | Yes | Yes |
Safety Considerations
The safety profile is consistent with lower semaglutide doses. Notable addition at 7.2mg: increased reports of altered skin sensation (sensitivity, pain, burning), generally resolving with dose reduction. The FDA is investigating further. Boxed warning for thyroid C-cell tumors applies.
Liv Body · from $199/mo
Explore GLP-1 Options →Compounded medications are not FDA-approved. Paid link
Availability and Alternatives
Wegovy HD launches mid-2026 in single-dose pen format. Current options remain available:
$130/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
from $147/mo
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
The Bottom Line
Wegovy HD closes the efficacy gap between semaglutide and tirzepatide. For patients who plateaued on standard doses, it's a meaningful step up in treatment intensity.
Sources
- FDA approval, Wegovy HD, May 13, 2026
- STEP UP trial (NCT05646706)
- Drug Topics, May 13, 2026